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1. Introduction
Pulmonary hypertension (PH) is a hemodynamic state defined by a resting mean pulmonary
artery pressure (PAP) at or above 25 mm Hg.[1] with normal left ventricular filling pressure
(mean pulmonary wedge pressure) 15 mmHg or less.
Pre-capillary PH is defined as mean PAP ≥25 mm Hg in association with PAOP ≤15 mm Hg
and a pulmonary vascular resistance (PVR) >3 Wood units. This include group 1, 3, 4 and 5
(Table 1). [2] Post-capillary PH (group 2 as shown in Table 1) is characterized by a mean PAP
≥25 mm Hg in association with PAOP >15 mm Hg and PVR ≤3 Wood units.[3] This differen‐
tiation in pre- and post-capillary PH is important as it narrows the differential diagnosis and
also has treatment implications.
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
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1.5 Persistent pulmonary hypertension of the newborn
1=. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis,
neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure
on dialysis.
ALK1 = activin receptor-like kinase type 1; BMPR2 = bone morphogenetic protein receptor type 2; HIV = human
immunodeficiency virus.
Adapted from Simonneau et al. Updated clinical Classification of pulmonary hypertension. J Am Coll Cardiol 2009; Vol.
54 (1): S43–54
Adapted with permission from ELSEVIER.(ref 11)
Table 1. Updated Clinical Classification of Pulmonary Hypertension (Dana Point, 2008)
2. Epidemiology
Pulmonary arterial hypertension (PAH) is a rare disease, with an estimated prevalence of 15-50
cases per million.[4] Idiopathic PAH (IPAH) has an annual incidence of 1-2 cases per million
people in the US and Europe and is 2-4 times as common in women as in men.[5], [6] The
REVEAL Registry demonstrates a 4.1:1 female-to-male ratio among patients with IPAH, and
a 3.8:1 ratio among those with associated pulmonary arterial hypertension (APAH). [4] The
mean age at diagnosis is around 45 years.[7] IPAH accounts for at least 40% of cases of PAH,
with APAH accounting for the majority of the remaining cases. [8]
The REVEAL Registry population tends to be overweight, with a BMI of 29 kg/m[2]; hence,
obesity may be a risk factor for the development of PAH. A variety of comorbid conditions
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were identified, including systemic hypertension, obstructive lung disease, sleep apnea, and
prior venous thrombo-embolism, which were not believed to represent the principal cause for
the patients’ pulmonary hypertension. [6]
The median interval from symptom onset to diagnosis remains unacceptably high at 1.1 years
in current registry data, [6] unchanged from the experience from the 1980's.[9] Overall survival
has improved somewhat, with 3-year survival of 48% in the NIH registry [10], compared to
67% in both US [11] and French [12] contemporary registries.
3. Etiology
Pulmonary arterial hypertension (PAH) is comprised of idiopathic, heritable and associated
forms. IPAH was previously referred to as primary pulmonary hypertension. During the 4th
World Symposium on pulmonary hypertension in 2008 at Dana Point, California, USA, the
group updated the Evian –Venice classification of 2003 of pulmonary hypertension based upon
mechanism. 2 (Table 1)
4. Pathophysiology
PAH is a proliferative vasculopathy which is histologically characterized by endothelial and
smooth muscle cell proliferation, medial hypertrophy, fibrosis and in-situ thrombi of the small
pulmonary arteries and arterioles.[13], [14]
Genetic mutations — Predisposition to pulmonary vascular disease may be related to genetic
mutations in the bone morphogenetic protein receptor type II (BMPR2), activin-like kinase
type 1, and/or 5-hydroxytryptamine (serotonin) transporter (5HTT) genes. Abnormal BMPR2
may play an important role in the pathogenesis of IPAH, with up to 25 percent of patients with
IPAH having abnormal BMPR2 structure or function. [15], [16], [17]
5. Pathobiologic basis of therapy
The pathophysiology of IPAH is not fully elucidated An elevated pulmonary vascular
resistance seems to result from an imbalance between locally produced vasodilators and
vasoconstrictors, in addition to vascular wall remodeling.
Three major pathobiologic pathways (nitric oxide, endothelin, and prostacyclin) play impor‐
tant roles in the development and progression of PAH.
5.1. Nitric Oxide (N.O)
The endothelium-derived relaxing factor nitric oxide (NO), a potent pulmonary vasodilator,
is produced in high levels in the upper and lower airways by nitric oxide synthase II (NOSII)
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and affects the pulmonary vascular tone in concert with the low NO levels that are produced
by nitric oxide synthase III (NOSIII) in the vascular endothelium. NO causes smooth muscle
relaxation and proliferation, maintaining the normal pulmonary vascular tone. Patients with
IPAH have low levels of NO in their exhaled breath, and the severity of the disease inversely
correlates with NO reaction products in bronchoalveolar lavage fluid. [18], [19]
5.2. Endothelin-1
Endothelin-1 is a peptide produced by the vascular endothelium that has potent vasoconstric‐
tive and proliferative paracrine actions on the vascular smooth muscle cells. The pulmonary
circulation plays an important role in the production and clearance of endothelin-1, and this
physiologic balance is reflected in the circulating levels of endothelin-1. Patients with pulmo‐
nary hypertension, IPAH in particular, have an increased expression of endothelin-1 in
pulmonary vascular endothelial cells, and serum endothelin-1 levels are increased in patients
with pulmonary hypertension.[20], [21]
5.3. Prostacyclin
The endothelium also produces prostacyclin (PGI2) by cyclooxygenase metabolism of
arachidonic acid. Prostacyclin causes vasodilation throughout the human circulation and is an
inhibitor of platelet aggregation by its action on platelet adenylate cyclase. The final enzyme
in the production of PGI2 is prostacyclin synthase. The remodeled pulmonary vasculature in
lung tissue obtained from patients with severe IPAH expresses lower levels of prostacyclin
synthase when compared with normal lung tissue. [22]
5.4. Remodeling
In IPAH, pulmonary vascular smooth muscle cells that normally have a low rate of multipli‐
cation undergo proliferation and hypertrophy. Those smooth cell changes arise from the loss
of the antimitogenic endothelial substances (e.g., PGI2 and NO) and an increase in mitogenic
substances (e.g., endothelin-1). Other stimuli arise from locally activated platelets, which
release thromboxane A2 and serotonin; thromboxane A2 and serotonin act as growth-
promoting substances on the vascular smooth muscle cells. Both are vasoconstrictors and
serotonin also promotes smooth muscle cell hypertrophy and hyperplasia. In addition to the
smooth muscle cell proliferation, abnormalities in extracellular matrix contribute to the medial
hypertrophy in PAH.[3] These lead to intimal narrowing and increased resistance to blood
flow.
An abnormal proliferation of endothelial cells occurs in the irreversible plexogenic lesion. The
plexiform lesions in IPAH have been considered an abnormal growth of modified smooth
muscle cells. These lesions are glomeruloid structures forming channels in branches of the
pulmonary artery. These may result from a deregulated growth of endothelial cells. [23]
Because the plexiform lesions bear some resemblance to the neovascularization induced by
malignant gliomas at both the morphological and immunohistochemical level, one might
hypothesize that the plexogenic vessels also represent a unique form of active angiogenesis.
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Vascular endothelial cell factor (VEGF) promotes endothelial cell proliferation and is identical
to the tumor factor responsible for inducing increased vascular permeability. Lung and brain
express high levels of VEGF messenger RNA, and hypoxia triggers the production of VEGF.
Furthermore, the presence of inflammatory cells in the perimeter of structurally altered vessels
suggests that inflammatory cell-derived cytokines and growth factors may participate in the
pathogenesis of PPH. Based on these results PPH may also represent a disorder of endothelial
cell differentiation and growth. [23]
5.5. Thrombosis
Blood thrombin activity is increased in patients with pulmonary hypertension, indicating
activation of intravascular coagulation, whereas soluble thrombomodulin, a cell membrane
protein that acts as an important site of thrombin binding and coagulation inactivation, is
decreased. In addition, PGI2 and NO, both inhibitors of platelet aggregation, are decreased at
the level of the injured endothelial cell. Circulating platelets in patients with PAH seem to be
in a continuous state of activation and contribute to the prothrombotic milieu by aggregating
at the level of the injured endothelial cells.[3]
5.6. Other Factors contributing to PAH
• Vasoactive intestinal peptide (VIP) (systemic vasodilator, decreases pulmonary artery
pressure and pulmonary vascular resistance, inhibits platelet activation and vascular
smooth muscle cell proliferation)
• Vascular endothelial growth factor (VEGF) & receptors (participate in angiogenesis, appears
to be disordered in PAH)
6. Signs and symptoms
Early symptoms are nonspecific. The most common symptoms include dyspnea, weakness
and recurrent syncope. Other symptoms include fatigue, angina, and abdominal distention.
Symptoms at rest are reported only in very advanced cases.[1], [24]
The physical signs of pulmonary hypertension include left parasternal lift, loud pulmonary
component of the second heart sound (P2), pansystolic murmur of tricuspid regurgitation,
diastolic murmur of pulmonary insufficiency, and right ventricular S3. Jugular vein distention,
hepatomegaly, peripheral edema, ascites, central cyanosis and cool extremities may be seen in
patients with advanced disease. [25] The lung examination is usually normal.
7. Investigations
Diagnostic approach is summarized in Figure 1.[25]
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Adapted with permission from ELSEVIER.(ref 25)
Figure 1. Diagnostic Approach to Pulmonary hypertension. 6 MWD indicates 6-minute walk test; ABGs, arterial
blood gases; ANA, antinuclear antibody serology; CHD, congenital heart disease; CPET, cardiopulmonary exercise test;
CT, computerized tomography; CTD, connective tissue disease; CXR, chest X-ray; ECG, electrocardiogram; HIV, human
immunodeficiency virus screening; Htn, hypertension; LFT, liver function test; PE, pulmonary embolism; PFT, pulmona‐
ry function test; PH, pulmonary hypertension; RA, rheumatoid arthritis; RAE, right atrial enlargement; RH Cath, right
heart catheterization; RVE, right ventricular enlargement; RVSP, right ventricular systolic pressure; SLE, systemic lupus
erythematosus; TEE, transesophageal echocardiography; VHD, valvular heart disease; and VQ Scan, ventilation-perfu‐
sion scintigram.
7.1. Electrocardiography
ECG results are often abnormal in patients with PAH, revealing right atrial enlargement, right
axis deviation, right ventricular hypertrophy, or large P wave and characteristic ST depression
and T-wave inversions in the anterior leads. [26] However, a normal ECG does not exclude a
diagnosis of PAH.
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7.2. Chest radiography
Radiographic signs of pulmonary hypertension include cardiomegaly or prominent central
pulmonary arteries. [26]
7.3. Computed tomography and lung scanning
High-resolution chest CT scanning and ventilation-perfusion (V/Q) lung scanning are fre‐
quently obtained to help exclude interstitial lung disease and thromboembolic disease.
Radiographically, PH is said to be more likely when the main pulmonary artery diameter
(MPAD) is > 29 mm (sensitivity 69%, specificity 100%) [27], [28] and/or the ratio of the main
pulmonary artery to ascending aorta diameter is >1 [29]. The most specific CT findings for the
presence of PH were both a MPAD > 29 mm and segmental artery-to-bronchus ratio of >1:1 in
three or four lobes (specificity 100%) [30]. An additional feature of PH is rapid tapering or
“pruning” of the distal pulmonary vessels.
7.4. Echocardiography
Echocardiography is extremely useful for assessing right and left ventricular function,
estimating pulmonary systolic arterial pressure, and evaluating for congenital anomalies and
valvular disease. [1],[24],[31], [32]
Systolic pulmonary artery pressure is estimated using tricuspid insufficiency jet velocity based
on the simplified Bernoulli's equation:
4 x (TRV)2+ RA pressure
Normal velocity is 2.0 – 2.5 m/s and a higher velocity indicates pulmonary hypertension,
especially if there is associated dilation or dysfunction of the right ventricle.
7.5. Right heart catheterization
Right heart catheterization measures right atrial pressure, mean pulmonary artery pressure
(mean PAP), pulmonary artery occlusion pressure (PAOP), cardiac output (CO) by thermo‐
dilution / indirect Fick and mixed venous oxygen saturation. Right heart catheterization
provides data to calculate the pulmonary vascular resistance (mPAP-PAOP)/CO and trans‐
pulmonary gradient (mPAP-PAOP). In addition right heart catheterization evaluates pulmo‐
nary vasoreactivity and helps in the diagnosis of left-to-right intracardiac shunts (e.g. ASD,
VSD and PDA).
The normal resting mean PAP is 14 ± 3 mm Hg. The normal PAOP is from 6-12 mmHg. The
normal pulmonary vascular resistance is 0.3-1.6 Wood Units. Transpulmonary gradient is
normally ≤ 12 mmHg. Pulmonary hypertension (PH) is present when mean pulmonary artery
pressure (PAP) is greater than 25 mm Hg. The severity of PH is further classified on the basis
of mean pulmonary artery pressure as mild (25 to 40 mm Hg), moderate (41 to 55 mm Hg), or
severe (> 55 mm Hg) [33] or mild to moderate when PVR is between 2.5 and 4.9 Wood units;
and severe when PVR > or =5.0 Wood units. [34]
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7.6. Exercise testing
This is very helpful to assess the efficacy of therapy. Severe exercise-induced hypoxemia
should cause consideration of a right-to-left shunt. Cardiopulmonary exercise assessment with
a widely available 6-minute walk test is commonly used to assess and track functional capacity.
[1],[10], [24],[35],[36] However, it lacks specificity in that it cannot be used to discern between
several causes of an impaired ability to walk.[10]
Additional Workup: includes:
• Pulmonary function testing with diffusing capacity (DLCO): Elevated pulmonary artery
pressure causes restrictive physiology. In patients with PAH, the diffusing lung capacity
for carbon monoxide (DLCO) is reduced to approximately 60% to 80% of that predicted.
• Overnight oximetry or polysomnography is useful in detecting obstructive sleep apnea
• Ventilation/perfusion (VQ) scanning Patients with PAH may reveal a relatively normal
perfusion pattern or diffuse, patchy perfusion abnormalities
• Pulmonary angiography performed to further evaluate or better define the anatomy in the
setting of chronic thromboembolic disease
• Rheumatologic serologies to look for auto-immune diseases.
• Thyroid function testing: There is an increased incidence of thyroid disease in patients with
PAH, which can mimic the symptoms of right ventricular failure. Consequently, it is advised
that thyroid function tests be monitored serially in all patients.
• B-Type Natriuretic Peptide (BNP): Brain natriuretic peptide (BNP) levels are elevated in
patients with pulmonary hypertension and correlate with the pulmonary artery pressure.
• Anti-HIV
• If chronic arterial oxygen desaturation exists, polycythemia should be present. Hyper‐
coagulable states, abnormal platelet function, defects in fibrinolysis, and other abnormalities
of coagulation are found in some patients with PAH.
8. Treatment
Despite advances in various treatments, there is no cure for pulmonary hypertension. The
goals of treatment for pulmonary hypertension are to treat the underlying cause, to reduce
symptoms and improve quality of life, to slow the growth of the smooth muscle cells and the
development of blood clots; and to increase the supply of blood and oxygen to the heart, while
reducing its workload.
An algorithm for treatment is shown in Figure 2. [37]
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Adapted with permission from ELSEVIER (ref 33)
Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N. Updated evi‐
dence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1
Suppl):S78-84.
Figure 2. Evidence-Based Treatment Algorithm. (Drugs within the same grade of evidence are listed in alphabetical
order and not order of preference). APAH = associated pulmonary arterial hypertension; ERA = endothelin receptor
antagonist; HPAH = heritable pulmonary arterial hypertension; IPAH = idiopathic pulmonary arterial hypertension; IV =
intravenous; PAH = pulmonary arterial hypertension; PDE-5 = phosphodiesterase type 5; SC = subcutaneous; WHO =
World Health Organization.
8.1. Medical treatment
8.1.1. General measures
• Oral anticoagulation improves survival in IPAH and is recommended in all these patients
unless there is a contraindication. [26]
• Supplemental oxygen should be used to maintain oxygen saturation greater than 90%,
especially because hypoxemia is a major cause of pulmonary vasoconstriction. Consider
supplemental oxygen for PAH patients who are planning air travel, as mild hypobaric
hypoxia can start at altitudes between 1500 and 2000 m, and commercial airliners are
pressurized to the equivalent of an altitude between 1600 and 2500 m.[31]. Results suggest
Pulmonary Arterial Hypertension: An Overview
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travelers with PH, who will be traveling on long flights or those with a history of oxygen
use, should be considered for supplemental in-flight oxygen.[32]. A flight simulation test
before the flight can help determine oxygen needs at altitude.[24],[35]
• Diuretics are indicated for right ventricular volume overload
• Digoxin is reserved for patients with refractory right ventricular failure and for rate control
in atrial flutter or fibrillation. [24],[35],[37]
• No specific diet is recommended; however, a low-sodium and low-fluid diet is recom‐
mended in patients with significant volume overload due to right ventricular failure.
• Exercise training is well tolerated and improves quality of life, WHO functional class, peak
oxygen consumption, oxygen consumption at the anaerobic threshold, and achieved
workload.[38] Patients with pulmonary hypertension and heart failure should perform mild
symptom-limited aerobic activity and avoid complete bed rest. Isometric exercises (weight
lifting) are contraindicated.
• Vaccination against influenza and pneumococcal pneumonia and avoidance of pregnancy.
9. Pulmonary vascular reactivity testing and vasodilator therapy
Diagnostic catheterization followed by pharmacological testing of vasodilator therapy
response is required to test the pulmonary vasoreactivity in patients with IPAH before
prescribing a vasodilator. The most commonly used drugs are: iv prostacyclin, iv adenosine,
inhaled nitric oxide and inhaled iloprost. Oxygen, nitroprusside, and hydralazine should not
be used as pulmonary vasodilator testing agents. A complete right heart catheterization and
an invasive monitoring of the systemic pressures are mandatory. The increased pulmonary
vascular resistance results from extensive vascular changes and vasoconstriction. Therefore,
in pulmonary hypertension true pulmonary vasodilation is only present if, in addition to a
decreased pulmonary vascular resistance, reductions in the transpulmonary gradient and the
mean pulmonary artery pressure are achieved.
A positive test or ‘responder to vasodilator’ is defined as a drop in mPAP of ≥ 10 mmHg to an
absolute level < 40 mmHg. A positive test is observed in 10-15% of patients with IPAH.
However half of these patients will have a long-term response to calcium channel blockers
(CCB). [39]
Only patients with an acute vasodilator response to an intravenous or inhaled pulmonary
vasodilator challenge (eg, with adenosine, epoprostenol, nitric oxide) derive any long-term
benefit from CCBs. Such patients constitute less than 15% of patients with IPAH and probably
less than 3% of patients with other forms of PAH. [24], [35], [39]
Patients who do not have an acute vasodilator response to a vasodilator challenge have a worse
prognosis on long-term oral vasodilator therapy compared with those who have an initial
response. These non-responders are those who have no significant change of the mean
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pulmonary vascular pressure or symptomatic systemic hypotension and no change or a
reduction of cardiac index (by more than 10 %), possibly accompanied by an increase in right
atrial pressure (by more than 20 – 25 %). However, the absence of an acute response to
intravenous or inhaled vasodilators does not preclude the use of intravenous vasodilator
therapy. In fact, continuous intravenous vasodilator therapy is strongly suggested for these
patients because CCBs are contraindicated. [40]
10. Calcium Channel Blocker therapy (CCB)
These drugs are thought to act on the vascular smooth muscle to dilate the pulmonary
resistance vessels and lower the pulmonary artery pressure. The use of CCBs should be limited
to patients without overt evidence of right-sided heart failure. In patients with IPAH (or any
other form of PAH), a cardiac index of less than 2 L/min/m2 or a right atrial pressure above 15
mm Hg is a contraindication to CCB therapy, as these agents may worsen right ventricular
failure in such cases.
10.1. Specific vasodilator therapy
These drugs in general work by dilating the pulmonary arteries and, therefore, by reducing
the pressure in these blood vessels and some help prevent the excessive overgrowth of tissue
in the blood vessels (that decrease remodeling of the vessels). Common side effects include
cough, flushing, and headache. Inhaled therapies may be useful as an adjunct to oral therapy.
There are three major classes of drugs used to treat pulmonary arterial hypertension:
10.2. Prostacyclins
Prostacyclin dilates systemic and pulmonary arterial vascular beds. These short acting drugs
include epoprostenol [41] (Flolan), treprostinil (Remodulin), iloprost [42] (Ventavis), Trepros‐
tinil (Tyvaso). Parenteral vasodilators are used for patients whose IPAH fails to respond to
calcium channel blockers or who cannot tolerate these agents and who have New York Heart
Association (NYHA) type III or IV right-sided heart failure.
Long-term treatment with intravenous PGI2 improves exercise capacity, hemodynamics, and
survival in most patients with PPH in NYHA functional class III or IV. Despite these favorable
outcomes, continuous intravenous infusion of PGI2 is not ideal due to its cost and side effects
such as flushing, headache, jaw pain, diarrhea and incidence of catheter-related infections.
Survival of patients with PPH treated with epoprostenol depends on the severity at baseline,
as well as the three-month response to therapy. Lung transplantation should be considered in
a subset of patients who remain in NYHA functional class III or IV or in those who cannot
achieve a significant hemodynamic improvement after three months of epoprostenol therapy,
or both. [40]
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10.3. Phosphodiesterase type 5 Inhibitors (PDE5i)
PDE5 inhibitors such as sildenafil [43] (Revatio, Viagra) is an orally active pulmonary vaso‐
dilators. (The dosing is much different when these drugs are used for erectile dysfunction).
These drugs promote selective smooth muscle relaxation in lung vasculature by inhibiting
PDE5 thereby stabilizing cyclic guanosine monophosphate (cGMP, the second messenger of
nitric oxide), allowing a more sustained effect of endogenous nitric oxide, an indirect but
effective and practical way of using the NO-cGMP pathway. Sildenafil improves exercise
capacity, World Health Organization (WHO) functional class, and hemodynamics in patients
with symptomatic pulmonary arterial hypertension. The main side effects of Sildenafil include
headache, flushing, dyspepsia, nasal congestion, and epistasis Nitrates should be avoided in
patients taking PDE5 inhibitors because the additive effects of the drugs may cause severe
systemic hypotension. [44]
10.4. Endothelin Receptor Antagonists (ERAs)
Endothelin-1 is a 21–amino acid peptide that plays a key role in the pathobiology of PAH,[45],
[46] exerting vasoconstrictor and mitogenic effects by binding to 2 distinct receptor isoforms
in the pulmonary vascular smooth muscle cells, endothelin A and B receptors.[47] Endothelin
B receptors also are present in endothelial cells, and their activation leads to release of
vasodilators and antiproliferative substances such as nitric oxide and prostacyclin that may
counterbalance the deleterious effects of endothelin-1.[47]
Bosentan is effective in patients with FC III / IV [48] but more recently bosentan was demon‐
strated to increase the 6 MWD from baseline in FC II patients as well [49]. Sitaxentan, a selective
endothelin (ET)-A receptor antagonist, has negligible inhibition of the beneficial effects of
ETB stimulation, such as nitric oxide production and clearance of ET from circulation. In clinical
trials, the efficacy of sitaxentan has been much the same as bosentan with reduced hepatotox‐
icity. [50] Dosing is once daily, as opposed to twice daily for bosentan.
Ambrisentan is a nonsulfonamide, propanoic acid– based, A-selective endothelin receptor
antagonist with a bioavailability and half-life that allow once-daily dosing. In the ARIES study
[51], Ambrisentan showed improvements in 6-minute walk distance in patients with WHO
functional class II and III symptoms. It is well tolerated and is associated with a low risk of
aminotransferase abnormalities. The most frequent side effects of ambrisentan are fluid
retention (ranging from swelling of the extremities to heart failure), nasal congestion, sinusitis,
flushing, palpitations, nasopharyngitis, abdominal pain and constipation.
ACCP guidelines recommend using the patient’s New York Heart Association (NYHA)
functional class to guide the choice of vasodilator therapy.[52] Grade A recommendations for
vasodilator therapy by functional class from the ACCP are as follows:
• Functional class II - Sildenafil
• Functional class III - Endothelin-receptor antagonists (bosentan), sildenafil, IV epoprostenol,
or inhaled iloprost
• Functional class IV - Intravenous epoprostenol.
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10.5. Combination therapy
Patients with PAH may experience clinical and hemodynamic deterioration despite treatment
with a single agent. This circumstance requires the addition on a second agent to slow disease
progression and aid in clinical improvement.[35],[37] Different combinations have been tried,
however current guidelines do not favor a particular combination over others. Several studies
are on-going to compare the efficacy of single agent versus combination therapy. Failure of
combination therapy requires consideration for parenteral therapy and surgical intervention
such as lung transplantation.
10.6. Surgery
10.6.1. Atrial septostomy
Atrial septostomy is a palliative procedure that may afford some benefit to patients whose
condition is deteriorating in the setting of severe disease with recurrent syncope or right heart
failure (or both) despite maximal medical therapy. The procedure can also be used as a bridge
to lung transplantation. The rationale for its use is that the controlled creation of an atrial septal
defect would allow right-to-left shunting, leading to increased systemic output and systemic
oxygen transport despite the accompanying fall in systemic arterial oxygen saturation. The
shunt at the atrial level would also allow decompression of the right atrium and right ventricle,
alleviating signs and symptoms of right heart failure. Balloon atrial septostomy is a high-risk
procedure and should be performed only in experienced centers to reduce the procedural risks.
[35],[37]
10.6.2. Lung transplantation
Lung transplantation has been used in treatment for pulmonary hypertension since the 1980s,
even before current medical therapies were available. It is indicated in PAH patients with
advanced disease that is refractory to available medical therapy. A single- or double-lung
transplant is indicated for patients who do not respond to medical therapy. Simultaneous
cardiac transplantation may not be necessary even with severe right ventricular dysfunction;
however, this depends on the transplant institution. The 3- and 5- year survival rates after lung
and heart-lung transplantation are approximately 55% and 45%, respectively. [35],[37]
10.6.3. Pulmonary thromboendarterectomy
Pulmonary thromboendarterectomy provides a potential surgical cure and should be consid‐
ered in all patients with chronic thromboembolic PAH (CTEPH) affecting central pulmonary
arteries. Pulmonary angiography is required to confirm surgical accessibility of chronic
thromboemboli. The procedure requires cardiopulmonary bypass and involves dissecting
well-organized thromboembolic material as well as part of the intimal layer of the pulmonary
arterial bed. Patients with suspected CTEPH should be referred to centers experienced in the
procedure for consideration of this procedure. In patients with operable CTEPH, pulmonary
Pulmonary Arterial Hypertension: An Overview
http://dx.doi.org/10.5772/56055
13
thromboendarterectomy is the treatment of choice because it improves hemodynamics,
functional status, and survival. [35],[37]
11. Considerations for special populations
11.1. Surgery
Elective surgery involves an increased risk in patients with PAH. The increased risk is
proportionate to the severity of the disease. It is not clear which type of anesthesia is advisable,
but probably local and regional anesthesia are better tolerated than general anesthesia. Surgery
preferably is performed at referral centers with experienced anesthesia and pulmonary
hypertension teams that can deal with potential complications.[36],[53] Anticoagulant
treatment should be interrupted for as short a period as possible. In patients with CTEPH,
bridging with heparin is recommended to minimize the time off anticoagulation.
11.2. Pregnancy
Although successful pregnancies have been reported in PAH patients, pregnancy and delivery
in PAH patients are associated with an increased mortality rate of 30% to 50%, and pregnancy
should be avoided or terminated. An appropriate method of birth control is highly recom‐
mended in all women with pulmonary hypertension who have childbearing potential.
Unfortunately, there is no current consensus on the most appropriate birth control method in
PAH patients. Because of the increased risk of thrombosis with estrogen-based contraception,
some experts suggest the use of estrogen-free products, surgical sterilization, or barrier
methods.[24], [35]
12. Natural history and prognosis
PAH has no cure. However, the rate of progression is highly variable and depends upon the
type and severity of the PAH. Untreated PAH leads to right-sided heart failure and death.
Prior to the 1990s, therapeutic options were limited. The emergence of prostacyclin analogues,
endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and other novel drug
therapies has greatly improved the outlook for patients with PAH.
For untreated IPAH, the estimated 3-year survival rate is approximately 41%. In one study of
long-term continuous intravenous prostacyclin therapy, 3-year survival increased to approx‐
imately 63%. [54] With newer therapies, perhaps in combination, these figures are expected to
improve further.
Less symptomatic patients in WHO class II/III, with normal right atrial and ventriclar size and
pressure and can walk more than 400 meters on 6 minute walk distance (MWD) are considered
lower risk group of patients for morbidity and mortality. While symptomatic patients in WHO
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class IV with signs of right heart failure, enlarged right atria and ventricle with right ventricular
dysfunction and cannot walk more than 300 meters on 6 MWD testing are considered high
risk group of pattients with pulmonary hypertension. [25], [55]
The one-year survival of patients with newly diagnosed group 1 PAH can be predicted using
a risk score derived from the Registry to Evaluate Early and Long-term PAH Disease Man‐
agement (i.e. the REVEAL registry). This risk score was validated by a prospective cohort study
of 504 patients with a mean 6-minute walk testing (6 MWD) of 308 m and 61.5 percent classified
as WHO functional class III, which found that a risk score of 1 to 7, 8, 9, 10 to 11, and ≥ 12
correlated with one-year survival of 95, 92, 89, 72, and 66 percent, respectively. [56]
Severity of PAH – Patients with severe PAH or right heart failure (i.e., cor pulmonale) die
sooner without treatment (usually within one year) than patients with mild PAH or no right
heart failure. As an example, patients with IPAH and a mean right atrial pressure ≥ 20 mmHg
have a median survival of approximately one month.[10]
In conclusion, age, PAH etiology, World Health Organization functional class, pericardial
effusion, 6MWT distance, the need for oxygen during the 6MWT, and brain natriuretic peptide
are predictors of prognosis in patients PAH receiving specific therapy and might help identify
a group that could benefit from aggressive upfront therapy. [57]
Since survival in patients who fall into NYHA classes III or IV is poor (9-18 months), patients
with severe symptoms and evidence of impaired cardiac function, which is refractory to
conventional therapy or epoprostenol infusion should be considered for lung transplantation.
Author details
Dr Saleem Sharieff MBBS, FCPS, FRCPC1,2
1 Grand River Hospital, Kitchener, ON, Canada
2 McMaster University Hospital, Hamilton, ON, Canada
References
[1] Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hyperten‐
sion. J Am Coll Cardiol 2004; 43:5S.
[2] Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmo‐
nary hypertension. J Am Coll Cardiol 2009; 54:S43-54.
[3] Ghamra ZW, Dweik RA. Primary pulmonary hypertension: an overview of epidemi‐
ology and pathogenesis. Cleve Clin J Med 2003; 70 Suppl 1:S2-8.
Pulmonary Arterial Hypertension: An Overview
http://dx.doi.org/10.5772/56055
15
[4] Peacock AJ, Murphy NF, McMurray JJV, et al. An epidemiological study of pulmona‐
ry arterial hypertension. Eur Respir J 2007; 30:104–9.
[5] Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719–25.
[6] Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline
characteristics from the REVEAL Registry. Chest 2010; 137:376–87.
[7] Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmona‐
ry arterial hypertension in the United States: how REVEAL differs from historic and
non-US Contemporary Registries. Chest 2011; 139:128–137.
[8] Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France:
results from a national registry. Am J Respir Crit Care Med 2006; 173:1023-30.
[9] Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national
prospective study. Ann Intern Med 1987; 107:216-223.
[10] D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary
hypertension. Results from a national prospective registry. Ann Intern Med 1991;
115:343-349.
[11] Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hy‐
pertension: 1982-2006. Eur Respir J 2007; 30:1103-1110.
[12] Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of pa‐
tients with pulmonary arterial hypertension. Eur Respir J 2010; 36:549-555.
[13] Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of
pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S.
[14] Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pul‐
monary hypertension. J Am Coll Cardiol 2004; 43:25S.
[15] Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene
PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
Am J Hum Genet 2000; 67:737.
[16] Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hy‐
pertension: current understanding and future directions. J Am Coll Cardiol 2004;
43:33S.
[17] Kimura N, Matsuo R, Shibuya H, et al. BMP2-induced apoptosis is mediated by acti‐
vation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol
Chem 2000; 275:17647.
[18] Kaneko FT, Arroliga AC, Dweik RA, et al. Biochemical reaction products of nitric ox‐
ide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit
Care Med 1998; 158:917-923.
Pulmonary Hypertension16
[19] Ozkan M, Dweik RA, Laskowski D, et al. High levels of nitric oxide in individuals
with pulmonary hypertension receiving epoprostenol therapy. Lung 2001;
179:233-243.
[20] Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary
hypertension: marker or mediator of disease? Ann Intern Med 1991; 114:464-469.
[21] Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs
of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-1739.
[22] Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased
in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care
Med 1999; 159:1925-1932.
[23] Tuder RM, Groves B, Badesch DB, VoelkelI NF. Exuberant endothelial cell growth
and elements of inflammation are present in plexiform lesions of pulmonary hyper‐
tension. Am J Pathol 1994, 144.275-285.
[24] Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment
of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pul‐
monary Hypertension of the European Society of Cardiology (ESC) and the Europe‐
an Respiratory Society (ERS), endorsed by the International Society of Heart and
Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
[25] McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier
MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, John Varga J. Ex‐
pert Consensus Document on Pulmonary Hypertension: A Report of the American
College of Cardiology Foundation Task Force on Expert Consensus Documents and
the American Heart Association. J Am Coll Cardiol. 2009; 53(17):1573-1619.
[26] Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmo‐
nary hypertension: natural history and the importance of thrombosis. Circulation.
1984: 70(4):580-7.
[27] Kuriyama K, Gamsu G, Stern RG, Cann CE, Herfkens RJ, Brundage BH. CT-deter‐
mined pulmonary artery diameters in predicting pulmonary hypertension. Invest Ra‐
diol. 1984;19:16–22.
[28] Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary
hypertension. Chest. 1997;112:980–986.
[29] Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension:
the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging. 1999;14:270–
278.
[30] Tan RT, Kuzo R, Goodman LR, et al. Utility of CT scan evaluation for predicting pul‐
monary hypertension in patients with parenchymal lung disease. Chest.
1998;113:1250–1256.
Pulmonary Arterial Hypertension: An Overview
http://dx.doi.org/10.5772/56055
17
[31] Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment
of pulmonary hypertension. Eur Respir J 2009; 34:1219-1263.
[32] McQuillan BM, Picard MH, Leavitt M, et al. Clinical correlates and reference inter‐
vals for pulmonary artery systolic pressure among echocardiographically normal
subjects. Circulation 2001; 104:2797-2802.
[33] Khan MG. Pulmonary hypertension and cor pulmonale. In: Khan MG, Lynch JP III,
eds. Pulmonary Disease Diagnosis and Therapy: A Practical Approach. Baltimore:
Williams & Wilkins, 1997:603–616.
[34] Chang PP, Longenecker JC, Wang NY, Baughman KL, Conte JV, Hare JM, Kasper
EK. Mild vs severe pulmonary hypertension before heart transplantation: different
effects on post transplantation pulmonary hypertension and mortality. J Heart Lung
Transplant. 2005 (8):998-1007.
[35] McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus
document on pulmonary hypertension: a report of the American College of Cardiolo‐
gy Foundation Task Force on Expert Consensus Documents and the American Heart
Association: developed in collaboration with the American College of Chest Physi‐
cians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association.
Circulation 2009; 119:2250-2294.
[36] Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pul‐
monary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Chest 2004; 126:63S-71S.
[37] Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm
in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S78-84.
[38] Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, Meyer FJ,
Karger G, Buss J, Juenger J, Holzapfel N, Opitz C, Winkler J, Herth FFJ, Wilkens H,
Katus HA, Olschewski H, Grunig E. Exercise and respiratory training improve exer‐
cise capacity and quality of life in patients with severe chronic pulmonary hyperten‐
sion. Circulation. 2006; 114: 1482–1489.
[39] Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of cal‐
cium channel blockers in pulmonary arterial hypertension. Respir Med 2010;
104:481-496.
[40] Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion
in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Car‐
diol 2002; 40:780–788.
[41] Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved
long-term effects and survival with continuous intravenous epoprostenol infusion. J
Am Coll Cardiol 1997; 30:343-9.
Pulmonary Hypertension18
[42] Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary
hypertension. N Engl J Med 2002; 347:322-9.
[43] Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intrave‐
nous epoprostenol therapy in patients with pulmonary arterial hypertension: a
randomized trial. Ann Intern Med 2008; 149:521-30.
[44] Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia
T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in
Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy
for pulmonary arterial hypertension. N Engl J Med. 2005; 353(20):2148-57.
[45] Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hyperten‐
sion. Cardiovasc Res. 2004;61:227–237.
[46] Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med.
2004;351:1655–1665.
[47] Davie N, Haleen S, Upton PD, Polak J, Yacoub M, Morrell N, Wharton J. ET(A) and
ET(B) receptors modulate the proliferation of human pulmonary artery smooth mus‐
cle cells. Am J Respir Crit Care Med. 2002; 165:398–405.
[48] Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor
antagonist bosentan in patients with pulmonary hypertension: a randomised place‐
bo-controlled study. Lancet 2001; 358:1119–23.
[49] Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A,
Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial
hypertension with bosentan (EARLY study): a double-blind, randomised controlled
trial. Lancet. 2008;371(9630):2093-100.
[50] Barst RJ, Langleben D, Badesch D, Frost A, Clinton Lawrence C, Shapiro S, Naeije R,
Galie N. Treatment of Pulmonary Arterial Hypertension With the Selective Endothe‐
lin-A Receptor Antagonist Sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049-2056.
[51] Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB,
McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin
LJ. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind,
Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation.
2008;117:3010-3019.
[52] Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial
hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;
131:1917-28.
[53] Kaw R, Pasupuleti V, Deshpande A, et al. Pulmonary hypertension: an important
predictor of outcomes in patients undergoing non-cardiac surgery. Respir Med 2011;
105:619-624.
Pulmonary Arterial Hypertension: An Overview
http://dx.doi.org/10.5772/56055
19
[54] Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxesentan
therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169
(4):441-7.
[55] McLaughlin VV, McGoon MD. Pulmonary Arterial Hypertension. Circulation. 2006;
114:1417-1431.
[56] Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score
calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest
2012; 141:354.
[57] Batal O, Khatib OF, Dweik RA, Hammel JP, McCarthy K, Minai OA. Comparison of
baseline predictors of prognosis in pulmonary arterial hypertension in patients sur‐
viving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac cathe‐
terization. Am J Cardiol. 2012: 15;109(10):1514-20.
Pulmonary Hypertension20
